Nordmark Arzneimittel GMBH & Co. KGAugust 12, 2019

FDA 483 - Nordmark Arzneimittel GMBH & Co. KG - August 12, 2019

View on Dashboard

Discuss this record with AI

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Nordmark Arzneimittel GMBH & Co. KG

Record Details

Nordmark Arzneimittel GmbH & Co. KG, an API and finished drug manufacturer in Uetersen, Germany, was cited for two significant issues during an FDA inspection. The inspection revealed inadequate controls over computerized systems, specifically concerning data integrity and audit trail review, and failures in adequately investigating and documenting deviations and customer complaints. These observations highlight deficiencies in critical quality system elements.

Company: Nordmark Arzneimittel GMBH & Co. KG
Inspection Date: August 12, 2019
Product Type: Drugs
Office: International Compliance Team
Person: Charles L. Zhou (Investigator)

Open in Dashboard

ID · fa4f589e-ae28-472d-955e-bf5887a2b503